Obstructive Sleep Apnea

17
Pipeline Programs
10
Companies
22
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
9
0
5
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Peptide
150%
+ 20 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
4 programs
1
2
JZP-110Phase 31 trial
JZP-110Phase 31 trial
JZP-110Phase 21 trial
Delphi Consensus Excessive Daytime Sleepiness in OSAN/A1 trial
Active Trials
NCT05055271Completed10Est. Sep 2022
NCT02806895Completed34Est. May 2019
NCT02348619Completed174Est. Nov 2016
+1 more trials
Teva
TevaIsrael - Petach Tikva
3 programs
2
Armodafinil 150 mg/dayPhase 31 trial
Armodafinil 250 mg/dayPhase 31 trial
PolysomnogramN/A1 trial
Active Trials
NCT01340781Completed110Est. Feb 2013
NCT00079677Completed263Est. Oct 2004
NCT00078325Completed395Est. Nov 2004
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
Maridebart cafraglutidePhase 3Peptide1 trial
Active Trials
NCT07226765Recruiting250Est. Sep 2028
Apnimed
ApnimedMA - Cambridge
9 programs
1
7
AD036Phase 21 trial
AD036 Dose 1Phase 21 trial
AD109Phase 21 trial
AD109 dose1- APhase 21 trial
AD113Phase 21 trial
+4 more programs
Active Trials
NCT06525337Active Not RecruitingEst. Mar 2025
NCT05101122CompletedEst. Apr 2022
NCT04445688CompletedEst. Dec 2020
+6 more trials
Mineralys Therapeutics
1 program
1
LorundrostatPhase 2Small Molecule1 trial
Active Trials
NCT06785454Completed48Est. Dec 2025
Bayer
BayerLEVERKUSEN, Germany
1 program
1
BAY2586116Phase 11 trial
Active Trials
NCT04872387Completed36Est. Aug 2021
Takeda
TakedaTOKYO, Japan
1 program
1
TAK-925Phase 11 trial
Active Trials
NCT04091425Completed25Est. Apr 2020
Great Lakes NeuroTechnologies
1 program
Autoadjusting CPAPN/A1 trial
Active Trials
NCT00588848TerminatedEst. Apr 2011
Advanced Brain Monitoring
1 program
Deliver therapy when the supine position is detectedN/A1 trial
Active Trials
NCT02032706CompletedEst. Feb 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AmgenMaridebart cafraglutide
Jazz PharmaceuticalsJZP-110
Jazz PharmaceuticalsJZP-110
TevaArmodafinil 150 mg/day
TevaArmodafinil 250 mg/day
Mineralys TherapeuticsLorundrostat
ApnimedAD113
ApnimedAD109 dose1- A
ApnimedAD182
ApnimedAD109
ApnimedAD036
ApnimedAD128
ApnimedAD036 Dose 1
Jazz PharmaceuticalsJZP-110
ApnimedDosing 1: Atomoxetine

Showing 15 of 22 trials with date data

Clinical Trials (22)

Total enrollment: 1,821 patients across 22 trials

NCT07226765AmgenMaridebart cafraglutide

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Start: Nov 2025Est. completion: Sep 2028250 patients
Phase 3Recruiting
NCT02348606Jazz PharmaceuticalsJZP-110

"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"

Start: May 2015Est. completion: Dec 2016476 patients
Phase 3Completed
NCT02348619Jazz PharmaceuticalsJZP-110

"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"

Start: May 2015Est. completion: Nov 2016174 patients
Phase 3Completed
NCT00079677TevaArmodafinil 150 mg/day

Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome

Start: Mar 2004Est. completion: Oct 2004263 patients
Phase 3Completed
NCT00078325TevaArmodafinil 250 mg/day

Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)

Start: Feb 2004Est. completion: Nov 2004395 patients
Phase 3Completed
NCT06785454Mineralys TherapeuticsLorundrostat

A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

Start: Feb 2025Est. completion: Dec 202548 patients
Phase 2Completed
NCT04905979ApnimedAD113

Trial of AD113 and Atomoxetine in OSA Patients With Hypertension

Start: Jul 2021Est. completion: May 2023
Phase 2Completed
NCT04631107ApnimedAD109 dose1- A

AD109 Dose Finding in Mild to Moderate OSA

Start: Dec 2020Est. completion: May 2021
Phase 2Completed
NCT04645524ApnimedAD182

Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea

Start: Dec 2020Est. completion: Sep 2021
Phase 2Completed
NCT04580394ApnimedAD109

Crossover Trial of AD109 in Obstructive Sleep Apnea

Start: Oct 2020Est. completion: May 2021
Phase 2Completed
NCT04445688ApnimedAD036

Crossover Trial of AD036 in Obstructive Sleep Apnea

Start: Jul 2020Est. completion: Dec 2020
Phase 2Completed
NCT04449133ApnimedAD128

Study of AD128 Versus Placebo in Obstructive Sleep Apnea

Start: Jul 2020Est. completion: Oct 2020
Phase 2Completed
NCT03845023ApnimedAD036 Dose 1

Trial of AD036 in Obstructive Sleep Apnea

Start: Mar 2019Est. completion: Oct 2019
Phase 2Completed
NCT02806895Jazz PharmaceuticalsJZP-110

Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA

Start: Jul 2016Est. completion: May 201934 patients
Phase 2Completed
NCT05101122ApnimedDosing 1: Atomoxetine

Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)

Start: Oct 2021Est. completion: Apr 2022
Phase 1/2Completed
NCT04872387BayerBAY2586116

A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the Body at Different Doses in Healthy Japanese Male Participants After Taking Single and Multiple Doses Through the Nose

Start: May 2021Est. completion: Aug 202136 patients
Phase 1Completed
NCT04091425TakedaTAK-925

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

Start: Nov 2019Est. completion: Apr 202025 patients
Phase 1Completed
NCT06525337ApnimedSTANDARDCARE

Adherence to Health Coaching with Wearable Devices: Enhancing Patient Engagement and Outcomes

Start: Aug 2024Est. completion: Mar 2025
N/AActive Not Recruiting
NCT05055271Jazz PharmaceuticalsDelphi Consensus Excessive Daytime Sleepiness in OSA

Delphi Consensus Excessive Daytime Sleepiness in OSA

Start: Apr 2021Est. completion: Sep 202210 patients
N/ACompleted
NCT02032706Advanced Brain MonitoringDeliver therapy when the supine position is detected

Validation of Safety and Efficacy for Night Shift Therapy

Start: Jun 2013Est. completion: Feb 2014
N/ACompleted
NCT01340781TevaPolysomnogram

Screening Tools for Obstructive Sleep Apnea (OSA) in Hospitalized Medical Patients

Start: Feb 2012Est. completion: Feb 2013110 patients
N/ACompleted
NCT00588848Great Lakes NeuroTechnologiesAutoadjusting CPAP

CPAP vs AutoCPAP for Treatment of Obstructive Sleep Apnea (OSA) in the Postoperative Setting

Start: Jan 2008Est. completion: Apr 2011
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,821 patients
10 companies competing in this space